Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Hematology · Therapy-Related Myelodysplastic Syndrome

What Causes Therapy-Related MDS After Chemo or Radiation?

At a Glance

Therapy-related MDS can develop after certain chemotherapy drugs or radiation, but treatment history alone cannot prove the cause. Doctors consider treatment type and dose, timing, bone marrow genetics, aging, and pre-existing mutations when assessing risk and treatment.

It is completely understandable to wonder if a past treatment or chemical exposure caused your Myelodysplastic Syndrome (MDS). When MDS develops after medical treatment for a prior cancer or condition, it is called therapy-related MDS (t-MDS) [1]. However, having had chemotherapy or radiation does not automatically mean the treatment caused your MDS. The disease is complex and often results from a combination of direct DNA damage, natural aging, and the expansion of pre-existing mutated cells (a process called clonal hematopoiesis) [1][2].

Medical Treatments vs. Environmental Exposures

While both can impact your bone marrow, doctors categorize them differently:

  • Therapy-related MDS (t-MDS): This strictly refers to disease following cytotoxic medical therapies, like chemotherapy or radiation.
  • Environmental/Occupational MDS: Environmental exposures, like the industrial chemical benzene, can cause DNA damage and increase the risk of developing MDS [3]. However, disease linked to benzene is generally classified as occupational or environmental MDS rather than “therapy-related.”

Which Cancer Treatments Are Linked to t-MDS?

Several classes of cancer treatments are known risk factors for developing t-MDS:

  • Chemotherapy: Alkylating agents (such as cyclophosphamide) and topoisomerase II inhibitors (such as etoposide) are the chemotherapy drugs most frequently associated with t-MDS [4]. The risk often increases with higher cumulative doses and more intense regimens [5][6].
  • Radiation Therapy: Radiation also carries a risk, especially when large areas of active bone marrow (like the pelvis or spine) receive higher doses [6].
  • Latency Period: The time from treatment to MDS diagnosis varies by therapy type. For example, topoisomerase II inhibitors often have a shorter latency (typically 1 to 3 years), while alkylating agents or radiation tend to have a longer latency (often 5 to 7 years or more) [7][8]. However, latency alone cannot prove or disprove that a specific treatment caused your MDS [7].

How Does t-MDS Differ from De Novo MDS?

Though diagnosed using the same blood and bone marrow criteria as standard (de novo) MDS, t-MDS tends to have different underlying genetics:

  • Chromosomal Changes (Cytogenetics): In some studies, up to 80% of t-MDS cases have chromosomal abnormalities, compared to roughly 40-45% in de novo MDS [9][10]. Patients with t-MDS are more likely to have a complex karyotype (an analysis showing three or more chromosomal abnormalities) and specific changes on chromosomes 5, 7, and 17 [9][11].
  • Genetic Mutations: Alterations in the TP53 gene are significantly more common in t-MDS (occurring in roughly 29% of cases in some cohorts, versus 7% in standard MDS) [10][12]. Conversely, mutations in spliceosome genes like SF3B1 are more frequent in de novo MDS [10].

No single genetic test can definitively prove that your MDS was caused by a prior treatment, but these patterns help your care team understand the biology of your disease [13].

How Does t-MDS Impact Risk Assessment and Treatment?

Because it often features higher-risk genetics, t-MDS generally carries a poorer prognosis than de novo MDS [11][14]. However, disease behaving like de novo MDS has been observed, particularly in some cases following radiation alone [11][15]. Your individual outlook depends on your specific test results.

  • Risk Assessment: Doctors commonly use scoring systems like the IPSS-R and IPSS-M to estimate risk [16][17]. While these tools are helpful, they were largely validated in standard MDS. Your doctor will interpret these scores carefully, factoring in your previous treatments and how they might have affected your heart, lungs, or kidneys [16].
  • Treatment Approach: Treatment is risk-adapted. It may include supportive care (like blood transfusions to manage symptoms), lower-risk targeted therapies, or hypomethylating agents (drugs like azacitidine or decitabine that help bone marrow function) for higher-risk disease [18][19].
  • Stem Cell Transplantation: An allogeneic hematopoietic stem-cell transplant (replacing your diseased bone marrow with healthy donor cells) is the only potentially curative option [20][21]. Meaningful long-term survival is possible for carefully selected patients, but previous cancer treatments can increase the risk of transplant-related complications and organ toxicity [22][23]. A prior cancer diagnosis is not an absolute barrier, and evaluation for transplant should happen early for eligible patients [22][24].

Common questions in this guide

Does chemotherapy or radiation automatically mean it caused my MDS?
No. MDS after treatment may be related to therapy, but the disease can also involve aging and the growth of pre-existing abnormal blood cells. Doctors consider the treatment type, dose, timing, and test results rather than assuming a cause.
Which cancer treatments are most closely linked to therapy-related MDS?
Two chemotherapy groups called alkylating agents, such as cyclophosphamide, and topoisomerase II inhibitors, such as etoposide, are commonly associated with therapy-related MDS. Radiation therapy may also raise risk, especially when large areas of bone marrow receive higher doses.
How long after chemotherapy or radiation can therapy-related MDS appear?
The timing varies by treatment. MDS after topoisomerase II inhibitors often appears within 1 to 3 years, while MDS after alkylating drugs or radiation often takes 5 to 7 years or longer. Timing alone cannot prove or rule out a treatment-related cause.
Does benzene exposure count as therapy-related MDS?
Benzene can damage DNA and increase the risk of MDS, but MDS linked to benzene is generally classified as environmental or occupational MDS. Therapy-related MDS specifically refers to MDS that develops after cytotoxic medical treatment.
How can doctors tell whether my MDS is therapy-related?
No single test can prove that prior treatment caused MDS. Doctors review the drugs, radiation fields, doses, and dates; the time until diagnosis; and blood, bone marrow, chromosome, and gene findings. This information helps classify the disease and estimate risk, but it may not establish certainty.
Is therapy-related MDS more serious than other forms of MDS?
Therapy-related MDS often has higher-risk chromosome or gene changes and a poorer outlook than MDS that develops without prior cancer treatment, but outcomes vary. Treatment is based on individual risk and may include transfusions, azacitidine or decitabine, and a stem-cell transplant using donor cells for selected patients.
Can I receive a stem-cell transplant after having cancer before?
A previous cancer diagnosis is not automatically a barrier to transplant. Eligibility depends on whether the original cancer is controlled, your overall health and organ function, the risk of your MDS, and the expected transplant risks. Evaluation should happen early if you may be eligible.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Does my cytogenetic and molecular testing (like my IPSS-M score) suggest my disease has high-risk features common in therapy-related MDS?
  2. 2.How does my history of prior chemotherapy or radiation impact my specific treatment plan and timeline?
  3. 3.Given my past cancer treatments and current organ function, am I a candidate for an allogeneic stem cell transplant, and what are the specific risks for me?
  4. 4.How might my prior therapies affect my ability to tolerate new medications or conditioning regimens for a transplant?
  5. 5.Is my original cancer considered fully controlled or in remission, and how does that factor into our MDS treatment goals?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

How Common Is MDS in the US, and What Age Is Typical?How Do ASXL1, TET2, SF3B1 Mutations Affect MDS Prognosis?How Do I Read an MDS Bone Marrow Biopsy Report Clearly?How Is VEXAS Syndrome Different From MDS? When to TestIs MDS Hereditary? When Should Relatives Be Tested?What Are the 31 Genes in the IPSS-M Risk Model for MDS?What Are the Limitations of IPSS-M for MDS Prognosis?What Conditions Can Mimic Myelodysplastic Syndrome?What Does del(5q) MDS Mean for Prognosis and Lenalidomide?What Does IPSS-M Mean for MDS Survival and Treatment?What Does MDS/AML Mean? Blast Percentage ExplainedWhat Do SF3B1 and Ring Sideroblasts Mean for MDS Prognosis?What Is the Difference Between CHIP, CCUS, and MDS?What Is Multi-Hit vs. Monoallelic TP53 in MDS? ExplainedHow Do WHO 2022 and ICC 2022 Classify MDS Differently?What Records and Slides Are Needed for an MDS Second Opinion?What Tests Are Included in a Complete MDS Diagnosis?Why Did My MDS Risk Score Change From IPSS-R to IPSS-M?Why Was MDS Renamed? Does It Change Treatment for Patients?

References

References (24)
  1. 1

    Can allogeneic hematopoietic cell transplant cure therapy-related acute leukemia?

    Madanat YF, Gerds AT

    Best practice & research. Clinical haematology 2019; (32(1)):104-113 doi:10.1016/j.beha.2019.02.011.

    PMID: 30927969
  2. 2

    Therapy-related myelodysplastic syndromes in the genomics era.

    Renneville A, Bernard E, Micol JB

    Bulletin du cancer 2023; (110(11)):1129-1140 doi:10.1016/j.bulcan.2023.02.022.

    PMID: 37391357
  3. 3

    A mechanism for 1,4-Benzoquinone-induced genotoxicity.

    Son MY, Deng CX, Hoeijmarkers JH, et al.

    Oncotarget 2016; (7(29)):46433-46447 doi:10.18632/oncotarget.10184.

    PMID: 27340773
  4. 4

    Myelodysplastic Syndrome in Patients with Gastro-Pancreatic Malignancies: A Case Series and Review of Literature.

    Godara A, Kumar A, Miller KB, Saif MW

    Cancer medicine journal 2021; (4(2)):52-59.

    PMID: 32685937
  5. 5

    Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials.

    Eichenauer DA, Becker I, Monsef I, et al.

    Haematologica 2017; (102(10)):1748-1757 doi:10.3324/haematol.2017.167478.

    PMID: 28912173
  6. 6

    Characteristics and Predictors for Secondary Leukemia and Myelodysplastic Syndrome in Ewing and Osteosarcoma Survivors.

    Sanford NN, Miao R, Wang H, et al.

    International journal of radiation oncology, biology, physics 2019; (103(1)):52-61 doi:10.1016/j.ijrobp.2018.08.037.

    PMID: 30165126
  7. 7

    Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias.

    Fianchi L, Pagano L, Piciocchi A, et al.

    American journal of hematology 2015; (90(5)):E80-5 doi:10.1002/ajh.23966.

    PMID: 25653205
  8. 8

    A monocentric retrospective study of 138 therapy-related myeloid neoplasms.

    Claerhout H, Lierman E, Michaux L, et al.

    Annals of hematology 2018; (97(12)):2319-2324 doi:10.1007/s00277-018-3462-y.

    PMID: 30203335
  9. 9

    Cytogenetics in the management of myelodysplastic neoplasms (myelodysplastic syndromes, MDS): Guidelines from the groupe francophone de cytogénétique hématologique (GFCH).

    Auger N, Douet-Guilbert N, Quessada J, et al.

    Current research in translational medicine 2023; (71(4)):103409 doi:10.1016/j.retram.2023.103409.

    PMID: 38091642
  10. 10

    The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution.

    Singhal D, Wee LYA, Kutyna MM, et al.

    Leukemia 2019; (33(12)):2842-2853 doi:10.1038/s41375-019-0479-8.

    PMID: 31089247
  11. 11

    Therapy-related MDS dissected based on primary disease and treatment-a nationwide perspective.

    Moreno Berggren D, Garelius H, Willner Hjelm P, et al.

    Leukemia 2023; (37(5)):1103-1112 doi:10.1038/s41375-023-01864-6.

    PMID: 36928008
  12. 12

    Comparison of therapy-related myelodysplastic syndrome with ring sideroblasts and de novo myelodysplastic syndrome with ring sideroblasts.

    Chen Z, Wang SA, Goswami M, et al.

    Leukemia research 2019; (86()):106227 doi:10.1016/j.leukres.2019.106227.

    PMID: 31557598
  13. 13

    De Novo and Therapy-Related Myelodysplastic Syndromes: Analogies and Differences.

    Leone G, Fabiani E, Voso MT

    Mediterranean journal of hematology and infectious diseases 2022; (14(1)):e2022030 doi:10.4084/MJHID.2022.030.

    PMID: 35615324
  14. 14

    Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium.

    Zeidan AM, Al Ali N, Barnard J, et al.

    Leukemia 2017; (31(6)):1391-1397 doi:10.1038/leu.2017.33.

    PMID: 28111463
  15. 15

    Myelodysplastic syndrome and acute myeloid leukemia following adjuvant chemotherapy with and without granulocyte colony-stimulating factors for breast cancer.

    Calip GS, Malmgren JA, Lee WJ, et al.

    Breast cancer research and treatment 2015; (154(1)):133-43 doi:10.1007/s10549-015-3590-1.

    PMID: 26450505
  16. 16

    Assessment and validation of the molecular international prognostic scoring system for myelodysplastic syndromes.

    Aguirre LE, Al Ali N, Sallman DA, et al.

    Leukemia 2023; (37(7)):1530-1539 doi:10.1038/s41375-023-01910-3.

    PMID: 37147425
  17. 17

    Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS.

    Kuendgen A, Nomdedeu M, Tuechler H, et al.

    Leukemia 2021; (35(3)):835-849 doi:10.1038/s41375-020-0917-7.

    PMID: 32595214
  18. 18

    Treatment of high-risk myelodysplastic syndromes.

    Kröger N

    Haematologica 2025; (110(2)):339-349 doi:10.3324/haematol.2023.284946.

    PMID: 39633555
  19. 19

    Clonal selection in therapy-related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment.

    Calleja A, Yun S, Moreilhon C, et al.

    European journal of haematology 2020; (104(5)):488-498 doi:10.1111/ejh.13390.

    PMID: 31990086
  20. 20

    Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the American Society for Transplantation and Cellular Therapy Committee on Practice Guidelines.

    DeFilipp Z, Ciurea SO, Cutler C, et al.

    Transplantation and cellular therapy 2023; (29(2)):71-81 doi:10.1016/j.jtct.2022.11.014.

    PMID: 36436780
  21. 21

    Comparison between Upfront Transplantation and different Pretransplant Cytoreductive Treatment Approaches in Patients with High-Risk Myelodysplastic Syndrome and Secondary Acute Myelogenous Leukemia.

    Schroeder T, Wegener N, Lauseker M, et al.

    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2019; (25(8)):1550-1559 doi:10.1016/j.bbmt.2019.03.011.

    PMID: 30880268
  22. 22

    Outcome of therapy-related myelodysplastic syndrome and oligoblastic acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: A propensity score matched analysis.

    Itonaga H, Kida M, Hamamura A, et al.

    Hematological oncology 2022; (40(4)):752-762 doi:10.1002/hon.2991.

    PMID: 35299289
  23. 23

    Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of TP53 mutational status.

    Aldoss I, Pham A, Li SM, et al.

    Haematologica 2017; (102(12)):2030-2038 doi:10.3324/haematol.2017.172544.

    PMID: 28971906
  24. 24

    Transplantation for myelodysplastic syndromes: who, when, and which conditioning regimens.

    Saber W, Horowitz MM

    Hematology. American Society of Hematology. Education Program 2016; (2016(1)):478-484 doi:10.1182/asheducation-2016.1.478.

    PMID: 27913519

This page is for informational purposes only and does not constitute medical advice. Your hematologist or oncologist can interpret whether prior treatments and test results may relate to your MDS.

Get notified when new evidence is published on Myelodysplastic syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.